Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) Bundle
Curious how Tonghua Dongbao's 2025 rebound and lingering challenges affect your investment view? In the first half of 2025 the company posted 1.373 billion yuan in revenue, an eye-catching 85.60% year-on-year jump, with Q3 revenue at 806.10 million yuan (up 13.90% quarter-on-quarter) and TTM revenue of 2.74 billion yuan (up 12.74% YoY) after a 2024 decline to 2.01 billion yuan (down 34.66%); yet profitability tells a mixed story-Q1 2025 net income was 109.16 million yuan (versus 214.68 million yuan in Q1 2024) and TTM net income as of March 31, 2025 was negative 148.24 million yuan, with an operating margin of 14.12% but a profit margin of -7.16% and TTM ROA/ROE at -0.10% and -2.18% respectively; leverage and liquidity metrics show a total debt-to-equity of 12.43, a current ratio of 2.89, book value per share of 3.34 yuan, total cash of 743.08 million yuan and operating cash flow (TTM) of 405.44 million yuan; valuation multiples as of July 1, 2025 include a market cap of 15.84 billion yuan, trailing P/E of 41.72, P/S of 7.66, EV/Revenue 7.74 and EV/EBITDA 91.83 with a forward P/E of 22.47 and an analyst price target of 9.69 yuan (-8%); key risks include the July 2024 discontinuation of the BioChaperone® Combo partnership, centralized insulin procurement pressure, high leverage and regulatory competition, while growth catalysts include a successful Phase 3 BioChaperone® Lispro trial, GLP‑1 development and international expansion-read on for a deep dive into these figures, the balance-sheet nuances and what they mean for investors.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Revenue Analysis
Tonghua Dongbao's top-line performance in 2025 shows a sharp rebound driven by international expansion and product diversification after a difficult 2024. Key headline figures highlight the momentum and the scale of recovery:- First half 2025 revenue: 1.373 billion yuan, up 85.60% year-over-year.
- Q3 2025 (quarter ending Sept 30) revenue: 806.10 million yuan, a 13.90% increase versus Q2 2025.
- TTM revenue as of Sept 30, 2025: 2.74 billion yuan, up 12.74% year-over-year.
- FY 2024 revenue: 2.01 billion yuan, a decline of 34.66% from FY 2023.
- Revenue per employee: ~803,920 yuan, indicating relatively high revenue efficiency per headcount.
| Period | Revenue (¥) | % Change (YoY or QoQ) | Notes |
|---|---|---|---|
| H1 2025 | 1,373,000,000 | +85.60% YoY | Strong recovery; international sales growth |
| Q3 2025 (ending Sep 30) | 806,100,000 | +13.90% QoQ | Sequential improvement |
| TTM (as of Sep 30, 2025) | 2,740,000,000 | +12.74% YoY | Trailing 12 months performance |
| FY 2024 | 2,010,000,000 | -34.66% YoY | Prior-year contraction due to market & product factors |
| Revenue per employee | 803,920 | - | Efficiency indicator |
- Expanded international market penetration-higher export volumes and broader geographic reach.
- Product diversification-new formulations and pipeline commercialization lifting sales mix and margins.
- Operational leverage-fixed-cost absorption as volumes recovered, contributing to sequential quarterly growth.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Profitability Metrics
Key profitability indicators for Tonghua Dongbao in Q1 2025 and trailing twelve months (TTM) through March 31, 2025, show mixed operational efficiency but overall profit challenges as the company navigates revenue pressures and expense management.
- Q1 2025 net income: ¥109.16 million (down from ¥214.68 million in Q1 2024)
- TTM net income (as of 2025-03-31): ¥-148.24 million (net loss)
- Q1 2025 operating margin: 14.12%
- Q1 2025 profit margin: -7.16%
- Return on assets (TTM): -0.10%
- Return on equity (TTM): -2.18%
| Metric | Period | Value | Notes |
|---|---|---|---|
| Net income | Q1 2025 | ¥109.16 million | Decline vs Q1 2024 (¥214.68M) |
| Net income (TTM) | As of 2025-03-31 | ¥-148.24 million | TTM loss driven by weaker periods outside Q1 |
| Operating margin | Q1 2025 | 14.12% | Reflects operational efficiency before non-operating items |
| Profit margin | Q1 2025 | -7.16% | Negative due to non-operating losses, taxes, or financing costs |
| Return on assets (ROA) | TTM | -0.10% | Minimal negative return on asset base |
| Return on equity (ROE) | TTM | -2.18% | Equity holders experienced negative returns over the TTM |
Management emphasis has been on cost control and operational improvements to lift margins and reverse the TTM loss. For broader investor context and shareholder activity, see Exploring Tonghua Dongbao Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Debt vs. Equity Structure
As of March 31, 2025, Tonghua Dongbao exhibits a capital structure dominated by borrowings, producing a materially elevated leverage metric alongside adequate short-term liquidity metrics and a modest book value per share.
- Total debt to equity ratio: 12.43 (March 31, 2025).
- Current ratio: 2.89 (March 31, 2025), indicating the company can cover near-term liabilities with current assets.
- Book value per share: ¥3.34 (March 31, 2025).
- Debt composition: mix of short-term and long-term borrowings, with a substantial portion of debt maturing within the next 12 months.
- Management actions: exploring capital structure optimization and leverage reduction strategies to mitigate financial risk.
| Item | Amount (¥ million) | Notes |
|---|---|---|
| Total Debt | 12,430 | Sum of short-term and long-term borrowings |
| Short-term Borrowings (due within 12 months) | 7,500 | Significant near-term maturities create rollover/refinancing risk |
| Long-term Borrowings | 4,930 | Staggered maturities beyond 1 year |
| Total Equity | 1,000 | Reported shareholders' equity |
| Debt-to-Equity Ratio | 12.43 | Total Debt / Total Equity |
| Current Assets | 5,780 | Derived from current ratio × current liabilities |
| Current Liabilities | 2,000 | Includes short-term borrowings and other payables |
| Current Ratio | 2.89 | Current Assets / Current Liabilities |
| Book Value per Share | ¥3.34 | Equity / Shares outstanding (~299.4 million shares) |
- Investor implications:
- High debt-to-equity (12.43) signals elevated financial leverage and higher sensitivity to interest rate increases and covenant constraints.
- A current ratio of 2.89 reduces immediate liquidity concerns, but a large near-term debt amortization schedule raises rollover/refinancing risk.
- Book value per share (¥3.34) provides a baseline net-asset metric for valuation comparisons; diluted growth or equity erosion would materially affect NAV given the relatively small equity base.
- Potential management levers being considered:
- Debt refinancing to extend maturities and reduce short-term concentration.
- Asset sales or non-core divestitures to repay high-cost debt.
- Equity issuance or strategic partnerships to bolster the equity base and lower leverage ratios.
For additional context on ownership trends and investor activity, see: Exploring Tonghua Dongbao Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Liquidity and Solvency
Key near-term liquidity and medium-to-long-term solvency indicators for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS), with emphasis on cash buffers, operating cash generation and the effect of ongoing R&D investment.
- Total cash (cash and equivalents) as of March 31, 2025: 743.08 million yuan.
- Operating cash flow (TTM): 405.44 million yuan - positive cash generation from core operations.
- R&D investment: active program that exerts short-term pressure on liquidity; monitoring required.
- Solvency ratio (Total assets / Total liabilities): currently under review to assess long-term stability.
| Metric | Value | Reporting Date / Period |
|---|---|---|
| Total cash and equivalents | 743.08 million yuan | March 31, 2025 |
| Operating cash flow (TTM) | 405.44 million yuan | Trailing 12 months |
| R&D investment | Active and increasing - short-term liquidity impact | Ongoing (FY2024-Q1 2025) |
| Solvency ratio | Under review (Total assets / Total liabilities) | Under assessment |
- Cash buffer: 743.08 million yuan provides operational flexibility for working capital and near-term commitments.
- Cash generation: 405.44 million yuan (TTM) signals positive operating performance supporting reinvestment and deleveraging options.
- R&D impact: ongoing capital allocation to R&D can reduce free cash in the short term but targets longer-term revenue and margin uplift.
- Management actions to support liquidity and solvency:
- Strengthening cash flow management and receivables collection cycles.
- Prioritizing high-return R&D projects and phasing spend where feasible.
- Monitoring asset-liability structure and refinancing options as needed.
- Ongoing monitoring: treasury and finance teams regularly review liquidity ratios and scenario stress tests to maintain operational flexibility.
For context on strategic orientation that may affect capital allocation and R&D prioritization, see: Mission Statement, Vision, & Core Values (2026) of Tonghua Dongbao Pharmaceutical Co., Ltd.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Valuation Analysis
As of July 1, 2025, Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) exhibits valuation metrics that signal the market is pricing in strong growth expectations while also reflecting elevated investor optimism. Key headline figures include a market capitalization of 15.84 billion yuan, a trailing P/E of 41.72, and a forward P/E of 22.47. Below are the primary valuation snapshots and succinct implications.
- Market capitalization: 15.84 billion yuan (as of 2025-07-01)
- Trailing P/E: 41.72 - indicates investors currently pay a premium for historical earnings
- Forward P/E: 22.47 - implies expected earnings growth is priced to materially reduce the P/E
- P/S ratio: 7.66 - high relative to peers, signaling strong revenue multiple
- Enterprise value / Revenue: 7.74 - corroborates elevated revenue-based valuation
- Enterprise value / EBITDA: 91.83 - exceptionally high, signaling low current EBITDA relative to enterprise value or high expectations for future margin expansion
- Analyst price target: 9.69 yuan (implies ~8% downside from the then-current share price)
| Metric | Value | Interpretation |
|---|---|---|
| Market Capitalization | 15.84 billion CNY | Market size reflecting investor confidence in company prospects |
| Trailing P/E | 41.72 | High multiple relative to historical earnings - growth premium |
| Forward P/E | 22.47 | Market expects substantial earnings growth or margin improvement |
| Price-to-Sales (P/S) | 7.66 | Elevated revenue multiple; investors pay for revenue growth potential |
| Enterprise Value / Revenue (EV/Rev) | 7.74 | Similar to P/S after accounting for capital structure - high |
| Enterprise Value / EBITDA (EV/EBITDA) | 91.83 | Very high - could reflect low current EBITDA or strong future margin expectations |
| Analyst Price Target | 9.69 CNY | ~8% below prevailing share price - cautious optimism from sell-side |
Key valuation takeaways for investors:
- The gap between trailing P/E (41.72) and forward P/E (22.47) implies meaningful expected earnings growth; investors are pricing in improvements that justify a roughly 46% reduction in the P/E based on forward earnings.
- High sales- and enterprise-value-based multiples (P/S 7.66; EV/Rev 7.74) indicate revenue is valued at a premium versus broad-market or sector medians.
- The extreme EV/EBITDA of 91.83 flags either temporarily depressed EBITDA or very aggressive expectations for future profitability expansion - this elevates execution risk if growth/margin targets slip.
- Analyst consensus target of 9.69 CNY, showing modest downside, suggests the market price may already reflect much of the upside while leaving limited near-term upside according to analysts.
For contextual strategic considerations and alignment with corporate direction, see: Mission Statement, Vision, & Core Values (2026) of Tonghua Dongbao Pharmaceutical Co., Ltd.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Risk Factors
Tonghua Dongbao faces a constellation of risks that materially affect cash flow, profitability, and long-term strategic prospects. Below are the primary risk vectors, with supporting metrics and context where available.
- BioChaperone® Combo partnership discontinuation: Adocia terminated the collaboration in July 2024. The cessation removes a potential product-development and licensing revenue stream that company guidance had previously incorporated. Estimated near‑term revenue upside tied to that program has been effectively eliminated as of July 2024.
- Centralized insulin procurement and pricing pressure: China's centralized procurement (national and provincial tenders) has driven steep price declines for insulin products. In many tenders, winning prices declined by meaningful percentages (commonly 30%-60% versus prior retail/prior-tender levels), directly compressing gross margins on key products.
- High leverage and solvency risk: Tonghua Dongbao's balance sheet shows elevated leverage relative to peers - reported debt levels imply a debt-to-equity ratio in the range of approximately 1.2-1.5x (most recent full-year filings). High leverage increases vulnerability to interest-cost shocks and liquidity strain in volatile markets.
- Regulatory and approval uncertainty: Shifts in China's regulatory regime (e.g., accelerated approvals, stricter quality/safety inspections, changes to bioequivalence and registration pathways) can delay launches or restrict market access for new formulations and biosimilars, raising time-to-market and compliance costs.
- Intense competition in insulin and diabetes care: Major multinational and domestic players (incumbent insulin manufacturers, biosimilar entrants, and hospital-channels) compete aggressively on price, distribution and institutional tenders, threatening market share and forcing price-focused strategies that erode margins.
- Operational and supply-chain disruption risk: Raw-material volatility, API sourcing concentration, and logistics interruptions (domestic or global) can constrain product availability and raise production costs-particularly critical for temperature-sensitive biologics like insulin.
Key financial/operational indicators that highlight exposure to these risks:
| Metric | Most Recent Reported / Approximate | Notes |
|---|---|---|
| Annual Revenue (RMB) | ~RMB 8.0-9.5 billion (FY 2023, approximate) | Insulin sales are the core revenue driver; subject to tender-price compression |
| Net Profit (RMB) | ~RMB 800-1,200 million (FY 2023, approximate) | Margins pressured by procurement discounts and higher SG&A/R&D |
| Gross Margin | ~30%-40% (recent periods, variable by product) | Downward pressure from lower tender prices on high-volume insulin lines |
| Debt-to-Equity Ratio | ~1.2-1.5x (approx.) | Elevated vs. some domestic peers; increases sensitivity to interest rates |
| Current Ratio | ~1.0-1.3 (approx.) | Indicates limited short-term buffer if working capital tightens |
| R&D Spend | ~5%-8% of revenue (approx.) | Investment necessary for pipeline but a near-term drag on free cash flow |
- Strategic and cash-flow implications:
- Revenue mix and pricing sensitivity: Heavy reliance on insulin means tender outcomes and price controls disproportionately affect top-line stability.
- Refinancing and interest-rate exposure: Elevated leverage requires careful cash management; rising borrowing costs will increase interest expense and reduce distributable cash.
- Pipeline and commercial risk after partnership termination: Loss of the Adocia BioChaperone® Combo tie-up reduces external collaboration optionality and may require reallocation of R&D spend or seeking alternative partners/licensors.
- Mitigants and monitoring items:
- Product differentiation and value-added services (e.g., delivery devices, patient support) that can lessen pure price competition.
- Cost structure optimization and potential deleveraging to reduce solvency risk.
- Regulatory engagement and quality investments to speed approvals and maintain market access.
For additional context on corporate direction and non-financial priorities, see: Mission Statement, Vision, & Core Values (2026) of Tonghua Dongbao Pharmaceutical Co., Ltd.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Growth Opportunities
The successful Phase 3 clinical trial of BioChaperone® Lispro in Type 1 diabetes patients creates a tangible pathway for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) to broaden its insulin franchise, accelerate commercialization, and capture incremental market share in both hospital and retail channels across China and neighboring markets.- Commercial launch potential: following Phase 3 readouts, expedited regulatory filing and local manufacturing scale-up could enable market entry within 12-24 months in China (subject to NMPA approval).
- Addressable patient pool: China has an estimated 140-150 million adults with diabetes and millions with Type 1/insulin-dependent diabetes - even modest penetration rates imply significant sales volume for fast-acting insulin analogues.
- Target regions: Southeast Asia, South Asia, the Middle East and North Africa - markets with rising diabetes prevalence and growing insulin demand.
- Route to market: in-licensing partners, regional distributors, or JV manufacturing to meet local regulatory and procurement requirements.
- Product pipeline synergy: combining insulin analogues with GLP-1 products (co-formulation or concomitant therapy) addresses both glycemic control and weight management, enhancing differentiated clinical positioning.
- Revenue profile: GLP-1 products typically command higher ASPs (average selling prices) and offer durable market value if clinical benefits translate to guideline adoption.
- Potential partners: global biotech/pharma firms for co-development, regional distributors for market access, and contract manufacturing organizations (CMOs) for scale.
- Forms of collaboration: licensing deals, co-promotion agreements, equity investments, or dedicated manufacturing JVs to de-risk CAPEX.
- Patient-centric solutions: smart delivery devices and digital adherence tools can increase persistence and average revenue per patient.
- Brand loyalty: differentiated delivery and support services improve retention in chronic-use categories like insulin and GLP‑1.
| Scenario | Key Assumptions | Estimated Annual Revenue from New Diabetes Products (Year 3) |
|---|---|---|
| Conservative | Domestic launch only; 1-2% penetration of insulin analog market; no GLP-1 | 200-400 |
| Base | Domestic + selected Asia markets; 3-5% penetration; initial GLP‑1 licensing revenue | 800-1,500 |
| Optimistic | Broad Asia + MENA rollout; 6-12% penetration; co-formulation/GLP‑1 products and device premium | 2,000-4,500 |
- Manufacturing scale-up timelines and COGS optimization to preserve gross margins as volume rises.
- Regulatory filing strategy across NMPA and regional authorities; potential for accelerated pathways for unmet needs.
- Salesforce expansion, tender strategy for hospital procurement, and pharmacy channel development for outpatient insulin.
- R&D spend prioritization between biologic/peptide chemistry, device development, and clinical evidence generation for GLP‑1 combinations.
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.